Resultado de búsqueda
13 de nov. de 2003 · We conducted the Valsartan in Acute Myocardial Infarction (VALIANT) trial to test the hypothesis that treatment with valsartan, an angiotensin-receptor blocker, alone or in combination with...
- Sudden Death in Patients with Myocardial Infarction and Left ...
VALIANT was a randomized, controlled trial of treatment with...
- Sudden Death in Patients with Myocardial Infarction and Left ...
Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) after ...
26 de sept. de 2018 · In the Valsartan in Acute Myocardial Infarction (VALIANT) trial, only half the patients with sudden death who underwent autopsy were found to have died from arrhythmic death. 34 In a...
Methods: Valsartan in Acute Myocardial Infarction (VALIANT) is a multicenter, double-blind, randomized, active controlled parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril, and their combination in high-risk patients after MI.
23 de feb. de 2010 · The goal of the trial was to evaluate the effect of the angiotensin-receptor blocker (ARB) valsartan, the angiotensin-converting enzyme (ACE) inhibitor captopril, and the combination of the two on mortality in patients with myocardial infarction (MI) complicated by left ventricular (LV) systolic dysfunction, heart failure, or both.
13 de nov. de 2003 · Conclusions: Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival. Copyright 2003 Massachusetts Medical Society. Publication types. Clinical Trial. Multicenter Study.
